濮阳东方技术安全放心(濮阳东方网络咨询) (今日更新中)

BEIJING, March 17 (Xinhua) -- The People's Bank of China (PBOC), or the central bank, auctioned 50 billion yuan (7.61 billion U.S. dollars) of three-month bills at a yield of 2.7944 percent on Thursday, temporarily easing speculation of an approaching interest rate hike.The yield on three-month bills stood unchanged from last week at 2.7944 percent.Also, PBOC sold 60 billion yuan (9.13 billion U.S. dollars) worth of 91-day repurchase agreements to banks on Thursday with a yield of 2.8 percent.Offsetting the 181 billion yuan (27.55 billion U.S. dollars) of bills and repurchase agreements that matured, PBOC took 49 billion yuan (7.46 billion U.S. dollars) of liquidity out of the money market this week through open market operations on Tuesday and Thursday.Market analysts have been watching PBOC's open market operations closely this week as the yield of its one-year bill sold on Tuesday exceeded the benchmark interest rate of one-year deposits, which some analysts interpret as a reason for an imminent interest rate hike.Chen Lan, an analyst with Guotai Junan Securities, said higher yields on central bank bills would boost PBOC's ability to absorb liquidity from the market amidst the country's economic tightening efforts."But the hike of interest rates is not an imminent task for the central bank amid the slowdown of China's industrial investment in February, which weakened consumer confidence, and economic uncertainty overseas," Chen said.China's industrial value-added output grew 14.1 percent in the first two months of this year, the National Bureau of Statistics (NBS) announced on Friday.The growth rate during the first two months was up by 0.6 percentage points compared to that in December of last year, according to figures released by the NBS.Chen predicted that PBOC will reduce its frequency to raise banks' reserve requirement ratio in coming months but said the rate hike expectation would continue this year as the government is hoping to curb the red hot property market and soaring inflation.China's consumer price index (CPI), a main gauge of inflation, rose 4.9 percent year on year in February, adding more monetary tightening pressure to the government. 

BEIJING, March 21 (Xinhuanet) -- A new device is being developed by American engineers to ease pain of blood sugar testing in diabetics, according to foreign media report last week.The upcoming device is the research target of a team of engineers at Arizona State University. It is specifically designed for patients with type1diabetes and type2 diabetes, according to a report in the "Journal of Diabetes Science and Technology,"  The traditional method of testing blood sugar levels involves painful pricks on the fingers to draw blood for testing. The inconvenient and painful process may somehow leave diabetics lax in their testing. The blood sugar levels, when poorly controlled, are very likely to trigger complications including heart disease, kidney disease and retinopathy.Unlike the old testing method, the new device could help people keep track of their blood sugar levels without the need to break the skin. It draws tears to measures the blood sugar levels in the fluid and gives just an accurate reading of blood sugar levels. "This new technology might encourage patients to check their blood sugars more often, which could lead to better control of their diabetes by a simple touch to the eye." said Jeffrey T. LaBelle, developer of the device.The new testing device has drawn great interest from investors due to its promising prospects. However, it still awaits a significant amount of testing before it can hit the market.

VIENNA, March 28 (Xinhua) -- Stress hormone is helpful in alleviating acrophobia, a morbid fear of great heights, according to a study by Austrian scientists.They published the findings in the recent Proceedings of the National Academy of Sciences of the United States of America.Frank H. Wilhelm, professor from the Department of Clinical Psychology, Psychotherapy and Health Psychology at the University of Salzburg, Austria, carried out the first study demonstrating the clinical effectiveness of hormones released at periods of high stress in anxiety.The study found hormones and other drugs could be a good addition to behavioral treatment of several anxiety disorders.People with acrophobia have formed a so-called fear memory, which could be activated when the fear-causing stimulus occurs. They tend to react with feelings of extreme fear and anxiety to the ride in a glass elevator.Hence, scientists conducted a confrontation therapy, trying to mask this memory.A total of 40 experimental subjects had been put in a safe environment to constantly confront the fear-inducing stimulus, until they had a new reaction to the perceived threat.Observations also suggested hormones released in high stress had impact on learning and memory.Additionally, stress hormones were believed to facilitate the storage of new, anxiety-free competence and experienced confidence in the therapy. Animal studies have shown that this emotional relearning benefits from cortisol, one of the stress hormones.

SAN FRANCISCO, April 25 (Xinhua) -- Yahoo Inc. on Monday announced that it has acquired IntoNow, a startup company whose technology can let users almost instantly recognize TV content and share favorite programs with their friends.IntoNow has built a technology platform that can automatically identify live television content and any previously aired U.S.- based television programming in the past five years.It also offers an application for iPhone and other devices running Apple's iOS operating system, which can help users connect and engage with their friends around the shows they love.With the application, users can find out what their friends are watching and engage in discussion through their favorite social networks, or discover what shows they have in common with others and which of them are on air right now."Relying on social channels as a means for discovering content - - whether it's on a PC, mobile device, or TV -- is rapidly on the rise," Bill Shaughnessy, Yahoo's senior vice president of product management and product marketing, said in a statement."IntoNow's technology combines the ability to check-in to what a consumer is watching, engage in conversations, and find related content," he added.In a post on its company blog, Yahoo noted that the addition of IntoNow will enhance its video programming, and bolster its social engagement across the Yahoo network and on all screens.IntoNow, headquartered in Palo Alto in the U.S. state of California, was only launched in January 2011 and now has seven employees.Yahoo didn't disclose terms of the purchase. Technology blog TechCrunch reported that Yahoo paid between 20 million to 30 million U.S. dollars, citing sources with knowledge of the deal.

WASHINGTON, April 6 (Xinhua) -- A study led by researchers at the University of Michigan (U-M) showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppresser function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53."For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.Wang presented the study Wednesday at the American Association for Cancer Research 102nd annual meeting.Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and Sanonfi-Aventis, researchers showed that these new drugs shrank tumors without significant side effects.Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.

来源：资阳报